James L. Gulley

National Cancer Insitute

Dr. Gulley serves within the Center for Cancer Research (CCR) of the National Cancer Institute, National Institutes of Health as Chief of the Genitourinary Malignancies Branch, Director of the Medical Oncology Service and Head of the Immunotherapy Section. He is an internationally recognized expert in immunotherapy for cancer. He has been instrumental in the clinical development of Prostvac, an experimental prostate cancer vaccine developed within the CCR and is the principal investigator of the international Prospect Trial, an international randomized phase 3 study of Prostvac. He also has been instrumental in the development of avelumab, an anti-PDL1 antibody that the first-in-human study was done at the CCR and was FDA approved in the Spring of 2017 based in part on the international study he leads. He is also the principal investigator on two other international studies of immunotherapy.

Dr. Gulley is most excited about the potential for combination therapy and has made significant contributions to combination therapy (therapeutic vaccine combined with each of the following: external beam radiation therapy, radionuclide, chemotherapy and most recently immune checkpoint modulation). The latter immune / immune combination therapy holds significant promise and Dr. Gulley is leading efforts to expand the clinical utility of immune checkpoint modulators into non-T-cell inflamed tumors through combination with therapeutic vaccines and other immunotherapies. Dr. Gulley has received numerous awards including the Presidential Early Career Award for Scientists and Engineers (PECASE), the highest award bestowed by the US government on outstanding scientists early in their careers. He has been an investigator on >120 trials, authored >250 scientific papers or chapters, and has made numerous presentations at national and international meetings.

Presentation(s):

Send Email for James Gulley